Department of Experimental Surgery - Cancer Metastasis, Medical Faculty Mannheim, Theodor Kutzer Ufer 1-3, 68135, Mannheim, Ruprecht Karls University of Heidelberg, Germany; Centre for Biomedicine and Medical Technology Mannheim (CBTM), Medical Faculty Mannheim, Ludolf-Krehl-Str. 6, 68135, Mannheim, Ruprecht Karls University of Heidelberg, Germany.
Department of Experimental Surgery - Cancer Metastasis, Medical Faculty Mannheim, Theodor Kutzer Ufer 1-3, 68135, Mannheim, Ruprecht Karls University of Heidelberg, Germany; Centre for Biomedicine and Medical Technology Mannheim (CBTM), Medical Faculty Mannheim, Ludolf-Krehl-Str. 6, 68135, Mannheim, Ruprecht Karls University of Heidelberg, Germany.
Semin Cancer Biol. 2020 Feb;60:1-13. doi: 10.1016/j.semcancer.2019.07.018. Epub 2019 Jul 27.
Metastasis still poses the highest challenge for personalized therapy in cancer, partly due to a still incomplete understanding of its molecular evolution. We recently presented the most comprehensive whole-genome study of colorectal metastasis vs. matched primary tumors and suggested novel components of disease progression and metastasis evolution, some of them potentially relevant for targeted therapy. In this review, we try to put these findings into perspective with latest discoveries of colleagues and recent literature, and propose a systematic international team effort to collectively define the "metastasome", a term we introduce to summarize all genomic, epigenomic, transcriptomic, further -omic, molecular and functional characteristics rendering metastases different from primary tumors. Based on recent discoveries, we propose a revised metastasis model for colorectal cancer which is based on a common ancestor clone, early dissemination but flexible early or late stage clonal separation paralleling stromal interactions. Furthermore, we discuss hypotheses on site-specific metastasis, colorectal cancer progression, metastasis-targeted diagnosis and therapy, and metastasis prevention based on latest metastasome data.
转移仍然是癌症个体化治疗面临的最大挑战,部分原因是对其分子进化的认识仍不完整。我们最近对结直肠转移与匹配的原发肿瘤进行了最全面的全基因组研究,并提出了疾病进展和转移进化的新成分,其中一些可能与靶向治疗有关。在这篇综述中,我们试图将这些发现与同事的最新发现和最近的文献联系起来,并提出一个系统的国际团队努力,共同定义“转移组”,我们引入这个术语来总结所有使转移与原发肿瘤不同的基因组、表观基因组、转录组、进一步的组学、分子和功能特征。基于最近的发现,我们提出了一个修订的结直肠癌转移模型,该模型基于一个共同的祖先克隆,早期传播,但早期或晚期的克隆分离具有灵活性,与基质相互作用平行。此外,我们还根据最新的转移组数据讨论了关于特定部位转移、结直肠癌进展、转移靶向诊断和治疗以及转移预防的假说。